RIP1-IN-1
RIP1-IN-1 is an orally active RIP1 inhibitor with strong RIP1 binding affinity (Kd: 110 nM). RIP1-IN-1 exhibits strong anti-necroptosis activity. RIP1-IN-1 effectively inhibits the formation of necrosomes by blocking the phosphorylation of RIP1, RIP3 and MLKL signaling pathways. RIP1-IN-1 inhibits necroptosis and can be used in the study of acute liver injury.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C26H21N3O3
- 分子量:423.46
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
IC50 & Target
[1]|
RIPK1 110 nM (Kd) |
体外実験
RIP1-IN-1 (Compound N-1) (0-1.6 μM, 5-24 h) can effectively and dose-dependently inhibit Z-VAD-FMK (HY-16658B) induced necroptosis in HT-29 cells, as well as Z-VAD-FMK (HY-16658B) induced necroptosis in U937 cells[1].
RIP1-IN-1 exhibits strong anti-necroptosis activity in HT-29 cells (CC50: >50 μM EC50: 8.8 nM)[1].
RIP1-IN-1 (0.4 μM, 2-6 h) effectively prevents the phosphorylation of both RIP1 and RIP3 in HT-29 cells treated with Z-VAD-FMK (HY-16658B) in a time-dependent manner, thereby inhibiting the phosphorylation of the downstream target MLKL[1].
RIP1-IN-1 (0.097-400 nM, 5 h) inhibits RIP1/3 and MLKL phosphorylation in a dose-responsive manner[1].
RIP1-IN-1 (400 nM, 6 h) inhibits Z-VAD-FMK (HY-16658B) induced necrosome formation in HT-29 cells by blocking phosphorylation of the RIP1/RIP3/MLKL pathway, demonstrating its anti-necroptosis activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Z-VAD-FMK (30 μM) treated HT-29 cells
-
Concentration:0.097、1.562、25、400 nM
-
Incubation Time:2-6 h
-
Result:Prevented the phosphorylation of both RIP1 and RIP3 within 2-6 h and subsequently inhibited downstream target MLKL phosphorylation.
Reduced pRIP1, pRIP3, and pMLKL levels in a dose-dependent manner in the range of 0.097-400 nM.
Parmacokinetics
| Species | Dose | Route | T1/2 | Tmax | Plasma Concentration | MRT | Clearance (CL) | Vd | AUC | Bioavailability |
|---|---|---|---|---|---|---|---|---|---|---|
| Rat[1] | 10 mg/kg | i.g. | 0.82 h | 0.5 h | 726 ng/mL | 1.65 h | 116 mL/min/kg | 8.29 L/kg | 1.442 μg·h/mL | 26.3 % |
体内実験
RIP1-IN-1 (3 mg/kg, i.g. once a day for 14 consecutive days) shows protective effect in the CCl4-induced acute liver injury model in mice[1].
RIP1-IN-1 (10 mg/kg, i.g.) shows short half-life and high clearance in Sprague-Dawley rats[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice; Establishment of SIRS mice model by combining mTNF-α (65 μg/kg) and Z-VAD-FMK (200 μg/piece)[1]
-
Dosage:1, 3, 5 mg/kg (5 % DMSO and 95 % CMC-Na solution)
-
Administration:p.o.
-
Result:Significantly improved the survival rate of SIRS mice, reaching 20%, 50% and 90%.
Alleviated mTNF-α-induced hypothermia within 9 hours.
Significantly reduced serum IL-6 levels, indicating its anti-inflammatory effect.
-
Animal Model:Male ICR mice (6-8 weeks old), 0.01 % CCl4 induced acute liver injury mice model[1]
-
Dosage:1, 3, 5 mg/kg (5 % DMSO and 95 % CMC-Na solution)
-
Administration:i.g., once daily for 14 consecutive days
-
Result:Significantly reduced RIP1, RIP3, and MLKL phosphorylation in diseased mice, thereby restoring AST and ALT markers indicative of liver damage.
HE staining showed that the liver tissue structure was close to normal at a dose of 3mg/kg and 5mg/kg, and the damage was significantly reduced.
The result showed that ALT, AST, and IL-6 levels were significantly reduced and close to the normal range, indicating that it can play a protective role against acute liver damage.
Western Blot results showed that it can effectively inhibit phosphorylation and block the necroptosis pathway.
化学情報
-
分子量 423.46
-
分子式 C26H21N3O3
-
SMILES
CN1C2=CC=CC=C2OC[C@H](NC(C3=CC(C(C4=CC=CC=C4)=CC=N5)=C5C=C3)=O)C1=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
RIP1-IN-1 関連分類
HY-173185 関連分類
Powered by Bioz